Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | FABP1 | P07148 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246552 | 0.87 | HPGD (0.72) | RAB9ALMNAMAPK14NPC1KMT2A | |
| SCHEMBL12993420 | 0.85 | RAB9A (0.88) | RAB9ALMNANR1H4EPHX2MEN1 | |
| SCHEMBL5709300 | 0.83 | HPGD (0.84) | RAB9ALMNAMAPK14EPHX2NPC1 | |
| SCHEMBL8738321 | 0.82 | MAPK14 (0.76) | LMNAMAPK14KMT2AHPGDRAF1 | |
| SCHEMBL2649884 | 0.81 | FABP1 (0.57) | RAB9ALMNAMEN1NPC1KMT2A | |
| SCHEMBL12201899 | 0.80 | LMNA (0.73) | RAB9ALMNANR1H4EPHX2HDAC8 | |
| SCHEMBL7113776 | 0.80 | RAB9A (1.00) | RAB9ALMNANR1H4EPHX2MEN1 | |
| SCHEMBL10294810 | 0.80 | HTT (0.64) | RAB9ALMNAMAPK14NPC1KMT2A | |
| SCHEMBL4028259 | 0.80 | MEN1 (0.72) | RAB9ALMNANR1H4EPHX2MEN1 | |
| SCHEMBL257930 | 0.78 | HPGD (0.63) | RAB9ALMNAMAPK14NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | RAB9A 2262/4885LMNA 883/4885MAPK14 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.